晚期非小细胞肺癌患者接受抗程序性细胞死亡蛋白1治疗过程中淋巴组织的3'-脱氧-3'-18F-氟胸苷PET显像
研究纳入25例晚期非小细胞肺癌患者,在抗程序性细胞死亡蛋白1(anti-PD-1)治疗前及治疗后2周、6周行18F-FLT PET,评估脾、淋巴结和椎体骨髓增殖变化与肿瘤反应的关系。结果显示非进展组椎体SUVmax和PVV在2周和6周显著降低,6周时进展组ΔTVP0-6显著高于非进展组(中位17.0% vs -13.0%,P=0.0080),脾和淋巴结变化两组无显著差异。作者认为18F-FLT PET有助于监测各淋巴组织免疫变化,可能作为免疫检查点抑制剂治疗反应的生物标志物。
要点
- 非进展组椎体骨髓18F-FLT摄取在治疗2周和6周显著降低。
- 6周时进展组椎体总增殖变化率显著高于非进展组(中位17.0% vs -13.0%,P=0.0080)。
- 脾和淋巴结18F-FLT摄取变化在进展组与非进展组间无显著差异。
核心结论
- 在获得肿瘤反应的晚期非小细胞肺癌患者中,治疗开始6周后骨髓增殖降低,而脾和淋巴结未见降低。
- 18F-FLT PET有助于监测各淋巴组织的肿瘤免疫变化,可能作为免疫检查点抑制剂治疗反应的生物标志物。
研究设计与样本
- 研究纳入25例晚期非小细胞肺癌患者,在抗PD-1治疗开始前及开始后2周和6周行18F-FLT PET。
- 测定脾SUVmean、淋巴结SUVmax以及胸腰椎椎体的SUVmax、SUVmean、增殖椎体体积(PVV)和总椎体增殖(TVP),并结合血液检查数据。
- 评估治疗前后这些参数变化率与肿瘤反应的关系。
主要发现
- 进展组与非进展组基线淋巴组织18F-FLT摄取及血液检查数据无显著差异。
- 脾和淋巴结从基线至2周或6周的18F-FLT摄取变化在非进展组与进展组间无差异。
- 纵隔淋巴结摄取在2周时较治疗前有短暂升高趋势(中位SUVmax 2.19 vs 2.64,P=0.073)。
- 非进展组椎体SUVmax和PVV在2周和6周显著降低。
- 治疗开始后椎体18F-FLT摄取变化率在6周评估时进展组显著高于非进展组(中位ΔTVP0-6,17.0% vs -13.0%,P=0.0080)。
关键数值与推荐
- 纵隔淋巴结2周较治疗前中位SUVmax 2.19 vs 2.64,P=0.073。
- 6周时椎体ΔTVP0-6中位值进展组17.0% vs 非进展组-13.0%,P=0.0080。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-programmed cell death-1 (anti-PD-1) therapy has become the standard immunotherapy for patients with advanced non-small cell lung cancer (NSCLC). However, little is known about the organs influenced by PD-1 inhibitors on a patient's tumor immunity. We examined the changes in lymphoid tissue proliferation before and after PD-1 inhibitor treatment using 3'-deoxy-3'-[18F]-fluorothymidine (18F-FLT) positron emission tomography (PET). This study included 25 patients with advanced NSCLC who underwent 18F-FLT PET before and 2 and 6 weeks after the initiation of PD-1 inhibitor treatment. We determined the average standardized uptake value (SUVmean) in the spleen, maximum SUV (SUVmax) in the lymph nodes, and the SUVmax, SUVmean, proliferative vertebral volume (PVV), and total vertebral proliferation (TVP) in the thoracolumbar vertebral bodies using 18F-FLT PET and blood test data. The relationship between the rate of change in these parameters before and after treatment and the tumor response was evaluated. RESULTS: The baseline 18F-FLT accumulation in the lymphoid tissues or blood test data between the progressive disease (PD) and non-PD groups were not significantly different. In the spleen and lymph nodes, changes in 18F-FLT accumulation from baseline to 2 or 6 weeks did not differ between the non-PD and PD groups. However, mediastinal lymph node accumulation tended to increase transiently at week 2 compared to that before treatment initiation (median SUVmax 2.19 vs. 2.64, P = 0.073). Regarding changes in vertebral accumulation in the non-PD group, the SUVmax, and PVV were significantly lower at weeks 2 and 6. In the percent changes in 18F-FLT accumulation of the vertebrae after the treatment initiation, the PD group was significantly higher than the non-PD group at the 6-week evaluation (median ΔTVP0-6, 17.0% vs. -13.0%, P = 0.0080). CONCLUSIONS: In patients with advanced NSCLC who achieved a tumor response, proliferation decreased in the bone marrow, but not in the spleen or lymph nodes, 6 weeks after treatment initiation. 18F-FLT PET can help monitor changes in tumor immunity in each lymphoid tissue and may serve as a biomarker for the response to immune checkpoint inhibitor therapy.
引用
- Sato M, Umeda Y, Tsujikawa T, et al. 3'-deoxy-3'-18F-fluorothymidine PET imaging of lymphoid tissues in patients with advanced non-small cell lung cancer undergoing anti-programmed cell death-1 therapy. EJNMMI Res. 2025. PMID: 40167945. doi:10.1186/s13550-025-01225-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。